Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol/tetrahydrocannabinol - Indaptus Therapetuics

Next Previous
Drug Profile

Cannabidiol/tetrahydrocannabinol - Indaptus Therapetuics

Alternative Names: Accordion Pill- Cannabidiol/tetrahydrocannabinol; AP-cannabinoids; AP-CBD/THC; Tetrahydrocannabinol/cannabidiol - Indaptus Therapeutics

Latest Information Update: 28 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intec Pharma
  • Developer Indaptus Therapeutics
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Fibromyalgia; Pain

Most Recent Events

  • 28 May 2022 No recent reports of development identified for phase-I development in Fibromyalgia(In volunteers) in Israel (PO, Pill)
  • 28 May 2022 No recent reports of development identified for phase-I development in Pain(In volunteers) in Israel (PO, Pill)
  • 03 Aug 2021 Decoy Biosystems has merged with Intec Pharma to form Indaptus Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top